Interferon Alfa News and Research

RSS
Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

New data provides hope for HCV non-responders

New data provides hope for HCV non-responders

Results from Presidio’s PPI-668 Phase 1a-1b trial on chronic HCV

Results from Presidio’s PPI-668 Phase 1a-1b trial on chronic HCV

Study demonstrates possibility of curing hepatitis C without use of interferon

Study demonstrates possibility of curing hepatitis C without use of interferon

New combo drug helps suppress hepatitis C genotype 1 infection

New combo drug helps suppress hepatitis C genotype 1 infection

Boehringer Ingelheim announces new data from hepatitis C virus portfolio

Boehringer Ingelheim announces new data from hepatitis C virus portfolio

PROLOR receives U.S. patent allowance for CTP-modified interferons

PROLOR receives U.S. patent allowance for CTP-modified interferons

Innovative detection practices may prevent liver diseases

Innovative detection practices may prevent liver diseases

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

Experts must monitor new antiviral compounds for HCV treatment

Experts must monitor new antiviral compounds for HCV treatment

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

FDA lifts clinical hold on Hemispherx's Alferon LDO Phase II study for influenza prevention

FDA lifts clinical hold on Hemispherx's Alferon LDO Phase II study for influenza prevention

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Pharmasset initiates dosing in PSI-7977 exploratory study in HCV

Pharmasset initiates dosing in PSI-7977 exploratory study in HCV

Vertex submits NDA for telaprevir for treating hepatitis C

Vertex submits NDA for telaprevir for treating hepatitis C

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Achillion initiates ACH-1625 Phase II dosing for HCV infection

Achillion initiates ACH-1625 Phase II dosing for HCV infection